"id","name","uuid:ID","description","rationale","instanceType","label"
"StudyDesign_1","Study Design 1","540af0d3-d355-469c-98ca-6bdb019f3933","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign",""
